| Patent application number | Description | Published |
|---|
| 20080233150 | RESPIRATORY SYNCYTIAL VIRUS-VIRUS LIKE PARTICLE (VLPS) - The present invention discloses and claims virus like particles (VLPs) that express and/or contains RSV proteins. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing immunity to infections, including RSV. | 09-25-2008 |
| 20090017066 | NOVEL VLPS DERIVED FROM CELLS THAT DO NOT EXPRESS A VIRAL MATRIX OR CORE PROTEIN - The present invention discloses novel influenza virus-like particles (VLPs) that contain chimeric proteins or influenza membrane proteins. The chimeric proteins are derived from fragments of influenza membrane proteins fused to heterologous proteins. The invention includes antigenic formulations and vaccines comprising VLPs of the invention as well as methods of making and administering VLPs to vertebrates, including methods of inducing immunity to infections, such as influenza. | 01-15-2009 |
| 20100129401 | Functional Influenza Virus Like Particles (VLPs) - The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof. | 05-27-2010 |
| 20100143393 | NOVEL INFLUENZA M2 VACCINES - The present invention includes novel influenza antigenic formulations and vaccines that comprise influenza M2 peptide and VLPs comprising influenza M2 protein. The invention also includes methods of making and administering the novel antigenic formulation and vaccine. The invention also include methods of inducing immunity to ameliorate and/or prevent influenza infections in a subject. | 06-10-2010 |
| 20100143406 | METHODS OF ENHANCING PROTEIN INCORPORATION INTO VIRUS LIKE PARTICLES - The present invention comprises a method of increasing glycoprotein incorporation on the surface of VLPs, comprising expressing a nucleic acid encoding a chimeric glycoprotein in a host cell, wherein said chimeric glycoprotein comprises the transmembrane domain of an influenza hemagglutinin protein. The invention also embodies specific VLPs comprising said chimeric glycoproteins and methods of inducing immunity in an animal utilizing said VLPs. | 06-10-2010 |
| 20100184192 | AVIAN INFLUENZA CHIMERIC VLPS - This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs | 07-22-2010 |
| 20100330122 | VARICELLA ZOSTER VIRUS VIRUS-LIKE PARTICLES (VLPs) AND ANTIGENS - The present invention discloses novel Varicella Zoster Virus (VZV) virus-like particles (VLPs) comprising glycoprotein E of VZV. The invention also discloses vaccine formulations of the VZV-VLPs and methods of inducing an immune response in subjects. | 12-30-2010 |
| 20110008838 | CHIMERIC VARICELLA ZOSTER VIRUS VIRUS-LIKE PARTICLES - The present invention discloses novel chimeric Varicella Zoster Virus (VZV) virus-like particles (VLPs) comprising chimeric VZV glycoproteins. The invention also discloses vaccine formulations of the chimeric VZV-VLPs and methods of inducing an immune response in subjects. | 01-13-2011 |
